HRT Prescriptions for Women 45–54 Have Nearly Tripled. Here's What Changes — and What Doesn't

Between January 2017 and April 2026, hormone therapy use among women aged 45–54 seen in US outpatient care rose from roughly 24 per 1,000 to 68 per 1,000 — close to a tripling, and the steepest rise of any age group. The shift was flat until 2022 and then climbed sharply. It is the largest change in menopause prescribing in twenty years, and it means a rapidly growing number of women are now navigating perimenopause with a prescription in hand and a set of questions nobody has answered for them: what should feel different, how long should it take, and why does something still feel off?

Updated 2 November 2026: in October the American College of Physicians published its first guideline on treating hot flashes and night sweats, naming hormone therapy as the first-line option for perimenopausal and postmenopausal women. This article now covers what that guideline says, what it does not say, and what the 2026 evidence on heart health actually shows.

For two decades, the conversation about hormone therapy was conducted almost entirely in the language of risk. A woman who raised it with her GP could reasonably expect caution, hedging, or a flat no. Many were told they were too young. Many were told to wait until things got worse. Some were told nothing at all, because nobody mentioned it as an option.

That conversation is changing, and the prescribing data now shows it changing at scale. But a prescribing trend is not a personal answer, and the arrival of HRT into far more women’s lives has created a new and specific gap: an enormous amount of published material on whether to take hormone therapy, and remarkably little on what to do once you are on it.

This article is about the second question. It covers what the new data actually says, what hormone therapy reliably does, what it demonstrably does not do, and why the phrase “I feel better, but I still don’t feel like myself” is so common among women three months into treatment. It is not an argument for or against starting HRT — that decision belongs to you and your clinician, and nothing here should be read as a recommendation either way.

---

What the Data Actually Shows

The figures come from Epic Research’s Cosmos analysis, published 30 July 2026, covering 163,348,471 adult women seen in US outpatient care between January 2017 and April 2026. Across all ages, hormone therapy use rose from about 1.7% to about 3.6% — a near-doubling. Women aged 45–54 nearly tripled, and by the end of the study period had the highest use rate of any age band.

Two other patterns in the data are worth noticing, because they say something about how prescribing has changed rather than just how much. First, growth was driven by single-hormone products: progestin-only use grew around 3.3-fold and oestrogen-only around 2.3-fold, while combined oestrogen-plus-progestin stayed roughly flat. Second, the route shifted. Transdermal formulations — patches and gels — grew about 3.5-fold, and vaginal products nearly tripled, both outpacing tablets.

It is worth being precise about what this study can and cannot tell you, because a lot of the coverage has not been. The denominator is women who attended outpatient care, so the trend partly reflects who turns up to appointments, which changed considerably around 2020. The researchers used age bands as a proxy for menopausal status, which they describe as coarse — it does not cleanly separate perimenopausal from postmenopausal women. And it is US data. This is a prescribing trend, and a robust one. It is not a measure of how many women are in perimenopause, and it is not evidence that any individual woman should or should not be on treatment.

---

Why the Trend Turned When It Did

The flat stretch through 2022 and the steep climb afterwards has a fairly legible history behind it.

In 2002, the Women’s Health Initiative trial reported increased risks of heart disease, stroke, blood clots and breast cancer with combined oestrogen-plus-progestin therapy, and the FDA added prominent boxed warnings. Use among postmenopausal women in the US fell from roughly 27% in 1999 to under 5% by 2020. Subsequent reanalyses argued that the trial’s older study population overstated the risk for a typical woman starting treatment in her early fifties — the average participant was 63, well past the point at which most women would begin.

In November 2025, the FDA removed the boxed warnings relating to cardiovascular disease, breast cancer and dementia from oestrogen-containing products, citing newer evidence that the benefit-risk balance looks different when therapy begins within ten years of menopause onset. The boxed warning for endometrial cancer on systemic oestrogen-only products remains.

That decision is not universally welcomed among clinicians, and the debate about it is genuine and ongoing rather than settled. What is not in dispute is that the labelling change, and the broader shift in tone that preceded it, coincided with a sharp acceleration in prescribing that had already begun in 2023.

---

What the New ACP Guideline Says

On 6 October 2026, the American College of Physicians — the US body representing internal medicine doctors, the clinicians most women see for routine care — published a clinical guideline on drug treatments for hot flashes and night sweats in Annals of Internal Medicine. ACP’s announcement states plainly that it applies to perimenopausal as well as postmenopausal women who are seeking treatment.

The recommendation is ranked in three tiers. First line is hormone therapy: oestrogen combined with a progestogen for women who have a uterus, or oestrogen alone for women who do not. ACP rates this a strong recommendation on high-certainty evidence, which is the top grade its system gives. Second line, for women who cannot take or do not tolerate hormone therapy, is an SNRI antidepressant (desvenlafaxine or venlafaxine), a conditional recommendation on moderate-certainty evidence. Third line is an SSRI (escitalopram or paroxetine), gabapentin, or one of the newer neurokinin receptor antagonists (elinzanetant or fezolinetant). Those are also conditional recommendations, on low to moderate-certainty evidence.

The systematic review behind the guideline pooled 90 randomised trials. Oestrogen, with or without a progestogen, reduced both how often hot flashes happened and how severe they were. Most non-hormonal options reduced how often they happened but not how severe they were. The reviewers also judged oestrogen to be of high economic value, which matters in a health system where cost decides what gets prescribed.

Two further details are worth knowing. The guideline tells clinicians to ask women about these symptoms, because many women will not raise them on their own. And it asks for an informed decision, weighing benefits, harms, other health conditions, preferences, cost and access. In other words, “first-line” means it is the option to discuss first. It does not mean every woman should take it.

---

What the Guideline Doesn’t Say

A headline like “doctors now recommend HRT first” invites a broader reading than the guideline supports, so it is worth being precise.

It is about hot flashes and night sweats, and only those. It does not recommend hormone therapy to prevent heart disease, to protect bone, to treat low mood or anxiety, or to manage the transition in general. It also applies to women who want treatment. If your hot flashes are mild and you are coping, nothing in it says you should be on anything.

Most of its evidence comes from short trials. The reviewers say most studies were short-term and not designed to measure serious or long-term harms, and that harms data were limited. The guideline is confident that hormone therapy works for symptoms. It has much less to say about decades of use.

The long-term evidence mostly comes from women older than you. A Cochrane review updated in September 2026 looked at 24 randomised trials of hormone therapy taken for at least a year, covering 45,660 women. Nearly 70% of the data came from two trials (HERS and the Women’s Health Initiative). In most trials the average participant was over 60, only about 30% of women were aged 50–59 when they started, and only one of the 24 trials was in perimenopausal women. The authors also caution that the main results come from one oral regimen, which may not represent the hormone therapy prescribed today, when many women use patches or gels. If you are 46 and still having periods, the long-term safety evidence you are handed was mostly gathered in women fifteen or more years older, on different products.

None of this weakens the guideline’s central point. Hormone therapy is the most effective treatment for hot flashes. But “effective for symptoms” and “known to be safe for you over twenty years” are separate questions, and only the first one is settled.

---

What the 2026 Evidence on Heart Health Shows

The heart question is where the gap is widest, and two large studies published within weeks of each other in 2026 point in opposite directions.

The first, a UK Biobank analysis of 170,250 women aged 40–69, found that women who had used HRT had a 13% higher adjusted risk of atherosclerotic cardiovascular disease over follow-up, mostly from ischaemic stroke. The rise was largest among women who were perimenopausal (a hazard ratio of 1.28), and risk rose with five or more years of use.

The second, an analysis of the US SWAN cohort in JAMA Internal Medicine, followed 2,737 women who had hot flashes or night sweats, 755 of whom started hormone therapy. It used a design that imitates a series of trials, and found a 22% lower risk of cardiovascular events among women who started treatment, and 27% lower among those who started within ten years of menopause. The authors are careful: they warn of possible residual confounding, and they write that their findings should not be used to support hormone therapy for preventing heart disease.

Both studies are observational. They describe what happened to women who chose hormone therapy, not what hormone therapy itself caused, and they counted different women in different ways — the SWAN analysis only included women with symptoms who had never used hormones, verified from their medicine containers. Read together, they say something useful: the cardiovascular picture in perimenopause is genuinely unsettled, and it probably depends on who you are, when you start, and what you take.

That is why the decision stays with a clinician who knows your history. Blood pressure, migraine with aura, a personal or family history of clots or stroke, smoking, and the route of oestrogen all change the balance, and none of them is visible from a population study.

---

What HRT Reliably Does

For vasomotor symptoms — hot flashes and night sweats — hormone therapy is the most effective treatment available, with clinical trials reporting reductions in the range of 75–95%. For many women, this alone is transformative, largely because night sweats fragment sleep and fragmented sleep degrades nearly everything else in the transition.

Low-dose vaginal oestrogen — a different treatment from systemic HRT, with a different risk profile — is effective for vaginal dryness, discomfort during sex, and recurrent urinary symptoms. Its near-tripling in the Epic data is one of the quieter but more meaningful findings, because these are among the most under-reported symptoms in the whole transition and among the most treatable.

Systemic hormone therapy also helps preserve bone density, which matters because bone loss accelerates markedly around the final menstrual period and produces no symptoms at all until something breaks.

Those are the things HRT does well, and the fact that more women have access to them is straightforwardly good news.

---

What HRT Doesn’t Do

Here is the part that tends to go unsaid in the appointment.

Hormone therapy does not build muscle. Lean mass declines through the transition, and the intervention that changes that trajectory is resistance training — strength work two or more times a week, progressively loaded. A patch does not do this, and no dose adjustment will.

It does not improve cardiorespiratory fitness. That comes from training, not from a prescription.

It does not supply the nutrients your body now needs in greater quantity — protein at a level most women in their forties are not reaching, calcium and vitamin D for the bone story above, magnesium, B vitamins. Protein intake in particular is the single most common gap we see, and it interacts with the muscle point: resistance training without adequate protein produces disappointing results.

It does not fix blood sugar regulation on its own. Insulin sensitivity declines through the transition, and while oestrogen plays a real role in that mechanism, meal composition and timing remain the levers you control day to day.

And it does not make your cycle predictable. Women on cyclical HRT still have a rhythm; women on continuous therapy move into something closer to a steady state. Neither is the same as the cycle you had at 35, and neither removes the value of knowing what your body is actually doing this week.

---

The Plateau Nobody Names

The most common thing we hear from women three months into hormone therapy is some version of: the flashes have gone, I’m sleeping, and I still don’t feel like myself.

This is not a sign that the treatment has failed, and it is not a reason to conclude that the dose must be wrong — although that is worth raising with your clinician if symptoms genuinely have not moved. More often it is the predictable consequence of a treatment doing precisely what it is designed to do while everything outside its remit stays where it was.

If low energy was being driven partly by disrupted sleep and partly by insufficient protein and declining muscle mass, then fixing the sleep resolves part of the problem and leaves the rest intact. The improvement is real. The residue is also real. Naming the split is what turns a vague sense of disappointment into something you can actually work on.

The largest global perimenopause survey published this year — 17,494 women across 158 countries, in Menopause — found fatigue and physical or mental exhaustion at the top of the symptom list, reported by around 83% of respondents, ahead of hot flashes. Irritability, low mood and sleep problems followed closely. Notably, that survey excluded women on hormone therapy or hormonal contraception, as did the companion analysis published in July. Which means the two headline perimenopause datasets of 2026 systematically exclude the fastest-growing segment of the population the Epic data describes. If you are on HRT and still exhausted, you are not an anomaly — you are simply not in the studies.

---

What Still Needs Attention If You’re on HRT

None of this is a reason to do more. It is a reason to do the right things, and the list is shorter than the internet suggests.

Protein first. Aim to spread intake across the day rather than loading it into the evening meal, and treat breakfast as the meal most likely to be short. This is the foundation that makes strength training work.

Strength training twice a week, non-negotiably. Not as a body composition project, but as the only reliable lever on lean mass and bone. Load matters more than duration; two sessions of twenty-five minutes done properly beat five vague ones.

Keep tracking symptoms — arguably more, not less. Hormone therapy usually involves dose or formulation adjustments over the first six to twelve months, and those decisions are far better made against a record than against a recollection of a bad few weeks. This is the single most useful thing you can bring to a follow-up appointment.

Watch what didn’t move. Make the distinction explicitly: which symptoms resolved, which improved partially, which are unchanged. That map is what tells you whether the remaining work is medical or lifestyle.

Take the intimate symptoms seriously. Vaginal dryness and urinary symptoms respond to a specific, low-risk, locally-acting treatment, and they are the symptoms women are least likely to raise. Systemic HRT does not always resolve them.

Our full guide to what to eat and how to move on hormone therapy covers the nutrition and training side in considerably more detail.

---

What to Take to Your Next Appointment

Appointments are short, and the difference between a useful one and a frustrating one is usually preparation rather than luck.

Bring a symptom record covering at least the last four to eight weeks, with severity rather than just presence — a symptom you rate 4 out of 5 on eighteen days a month is a different conversation from one you mention as “sometimes bad.” Note what improved after starting or adjusting treatment and what did not. Bring your full medication list, including over-the-counter products and supplements, since interactions and duplications are common. If hot flashes are the main problem, it is reasonable to ask where you sit on the first-, second- and third-line options in the ACP guideline, and what in your own history — blood pressure, migraine, clots, stroke — changes that picture. And write down your two most pressing questions before you go in, because they are the ones most likely to evaporate under time pressure.

There is decent evidence that women describe their perimenopause symptoms more fully to strangers online than to clinicians, particularly the emotional and cognitive ones. A written record is a way around that — it says the thing for you.

---

What PeriFlow Does for Women on HRT

PeriFlow treats hormone therapy as a first-class part of the picture rather than an afterthought. When you tell it you are on HRT, the whole guidance model adapts: cyclical regimens keep a phase rhythm mapped to your therapy, and continuous regimens switch to a steady-state model that reads from your symptoms rather than from a cycle day you no longer have.

Daily symptom check-ins build the record that follow-up appointments run on, and the clinical export turns months of ratings into a structured document you can hand over. The nutrition engine holds the protein target and surfaces bone-relevant nutrients alongside it; the Move tab holds the two-sessions-a-week strength floor underneath whatever else your week looks like. Nothing in the app tracks or adjusts your dose — that is your clinician’s territory, deliberately and permanently.

You can see how the whole thing fits together on our how it works page.

---

The Reframe

A tripling of prescriptions in the 45–54 age band is, on balance, a correction of something that went wrong in 2002 — a generation of women who were not offered a treatment that many of them would have benefited from. That is worth being glad about.

But it also creates a new and quieter problem. The relief of finally being offered something can make it hard to say, three months later, that it did not fix everything — and the women most likely to stay quiet about the gap are the ones who had to fight hardest to be taken seriously in the first place.

Hormone therapy addresses the hormonal deficit. It does not address the muscle, the protein, the training, the sleep architecture, or the daily pattern of a body that is still in transition. Feeling better and still feeling off is not ingratitude and it is not failure. It is an accurate reading of a treatment doing its job while the rest of the work waits.

---

Know your phase. Nourish your body. Feel like yourself again.

PeriFlow tracks your perimenopause cycle — even when it’s irregular — and tells you exactly what to eat, when to fast, and how to move, adapted to the phase you’re actually in. On HRT, it adapts to your therapy instead of fighting it. Free 7-day trial.

Download PeriFlow